PT - JOURNAL ARTICLE AU - Tatiana Bremova-Ertl AU - Jen Claassen AU - Tomas Foltan AU - Jordi Gascón Bayarri AU - Paul Gissen AU - Andreas Hahn AU - Anhar Hassan AU - Anita Hennig AU - Simon Jones AU - Miriam Kolniková AU - Kyriakos Martakis AU - Uma Ramaswami AU - Reena Sharma AU - Susanne Schneider TI - Acetyl-L-leucine for Niemann-Pick type C – a multi-national, rater-blinded phase II trial AID - 10.1101/2020.12.22.20248704 DP - 2020 Jan 01 TA - medRxiv PG - 2020.12.22.20248704 4099 - http://medrxiv.org/content/early/2020/12/26/2020.12.22.20248704.short 4100 - http://medrxiv.org/content/early/2020/12/26/2020.12.22.20248704.full AB - Background Niemann-Pick disease type C (NPC) is a rare autosomal recessive neurodegenerative disorder characterized by symptoms such as progressive cerebellar ataxia and cognitive decline. The modified amino acid N-acetyl-leucine has been associated with positive symptomatic and neuroprotective, disease-modifying effects in observational case studies and animal and cellular models of NPC. Therefore, the effects of the active L-enantiomer, N-acetyl-L-leucine (NALL, Sponsor Code IB1001) were evaluated in paediatric and adult patients with NPC.Methods We conducted a 9-center, multinational, open-label, rater-blinded Phase 2 study to assess the safety and efficacy of NALL for the treatment of pediatric (≥ 6 years) and adult patients with NPC (IB1001-201 clinical trial). Eligible patients were assessed during three study phases: a baseline period (with or without a study run-in), a 6-week treatment period (dosage of NALL 4 g/d in patients aged ≥13 years; weight tiered doses for patients aged 6-12 years based on approximately 0.1 g/kg/day), and a 6-week post-treatment washout period. The primary outcome was based on the Clinical Impression of Change in Severity (CI-CS) assessment (assessed on a 7-point Likert scale) performed by blinded, centralized raters who compared videos of patients performing a pre-defined primary anchor test (either the 8-Meter Walk Test (8MWT) or 9-Hole Peg Test of the Dominant Hand (9HPT-D)) at different study periods. Secondary outcomes included the cerebellar function evaluations, namely the Scale for Assessment and Rating of Ataxia (SARA), the Spinocerebellar Ataxia Functional Index (SCAFI), and the Clinical Global Impression Scales (CGI) as well as the EuroQol-5D/VAS.Results Thirty-three subjects aged 7 to 64 years with a confirmed diagnosis of NPC were enrolled according to the trial protocol between 04 September 2019 and 30 January 2020. Thirty-two patients were included in the modified intention-to-treat analysis. IB1001 met its CI-CS primary endpoint (mean difference 0.86 ((90% CI 0.25,1.75, p=0.029). IB1001 also met secondary endpoints, including improvement during treatment on the SARA scale (mean difference −1.19 (90% CI −1.8, −0.5, p=0.001)), investigator’s CGI-C assessment (mean difference from baseline to the end of treatment 0.6 (90% CI 0.5, 1.0, p<0.001)), clinically worsening over the washout period on the SARA (mean difference 1.45 (90% CI 0.5, 2.0, p=0.002)) and investigator’s CGI-C assessment (washout mean difference −0.5 (90% CI −1.0, 0.0, p=0.006). IB1001 was well-tolerated with no treatment related serious adverse reactions occurring.Conclusions Consistent with its pharmacological action, IB1001 rapidly improved symptoms, functioning, and quality of life in 6-weeks, the clinical effect of which was lost after the 6-week, post-treatment washout period. High consistency and statistical significance between the primary and secondary endpoints demonstrate a clear, clinically meaningful improvement with IB1001. IB1001 was well-tolerated and no drug-related serious adverse events were reported, demonstrating a favorable risk/benefit profile for the treatment of NPC (Funded by IntraBio; ClinicalTrials.gov number, NCT03759639; EudraCT number 2018-004331-71).Competing Interest StatementCompeting interest: All authors have completed the ICMJE uniform disclosure form and declare: no support from any organisation for the submitted work; SS was supported by the Munich Clinician Scientist Programme, the Ara Parseghian Medical Research and the Verum Stiftung. TBE received honoraria for lecturing from Actelion and Sanofi Genzyme. AH Hassan has received previous support from AbbVie and NCATS, and serves on the Editorial Board of Parkinsonism and Related Disorders. UR has received research grants from Amicus and Takeda, advisory board and lecture fee from Amicus, Chiesi, Genzyme; no other relationships or activities that could appear to have influenced the submitted work.Clinical TrialClinicalTrials.gov number, NCT03759639; EudraCT number 2018-004331-71Clinical Protocols https://www.medrxiv.org/content/10.1101/2020.03.11.20034256v1 Funding StatementThe trial was sponsored and funded by IntraBio Ltd. A confidential agreement was executed with each Participating Organisation (i.e. trial site)/ its respective principal investigator in accordance with ICH GCP and applicable national clinical trial compensation guidelines which detailed how the Sponsor shall provide financial remuneration for the performance of the Clinical Trial to the Participating Organisation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The studies have been approved by the responsible central research ethics committees and institutional review boards, including the Ethics Committee of Ludwig Maximilian University of Munich (19135), National Institute of Child Diseases Bratislava Ethics Committee (EudraCT 201800443171), Bellvitge Hospital University Clinical Research Ethics Committee (AC00119); East Midlands, Derby Research Ethics Committee (259038); Mayo Clinic Institutional Review Board (18011974).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during and/or analysed during the current study are available from IntraBio Ltd. Due to confidentiality agreements with research collaborators, the data are not publicly available but are available from the corresponding author and with permission from IntraBio Ltd on reasonable request.